EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous CGM issues joint reasoned statement recommending that shareholders accept CVC's voluntary public takeover offer 03.01.2025 / 11:27 CET/CEST The issuer is solely responsible for the content of this announcement. CGM issues joint reasoned statement recommending that shareholders accept CVC's voluntary public takeover offer Offer price of EUR 22.00 per share is considered to be fair and adequate Deutsche Bank and J.P. Morgan have issued fairness opinions confirming the fairness of the offer price fr...
EQS-News: CompuGroup Medical SE & Co. KGaA / Schlagwort(e): Sonstiges CGM veröffentlicht begründete Stellungnahme und empfiehlt den Aktionären die Annahme des freiwilligen öffentlichen Übernahmeangebots von CVC 03.01.2025 / 11:27 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CGM veröffentlicht begründete Stellungnahme und empfiehlt den Aktionären die Annahme des freiwilligen öffentlichen Übernahmeangebots von CVC Angebotspreis von EUR 22,00 pro Aktie wird als fair und angemessen angesehen Deutsche Bank und J.P. Morgan bestäti...
EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous CompuGroup Medical enters into an investment agreement with CVC Capital Partners 09.12.2024 / 09:19 CET/CEST The issuer is solely responsible for the content of this announcement. CompuGroup Medical enters into an investment agreement with CVC Capital Partners CVC announces intention to launch a voluntary public tender offer to all free float shareholders CVC to launch voluntary public tender offer for EUR 22.00 per share, subsequent delisting envisaged Significant premium of 51.1% to the 3M V...
EQS-News: CompuGroup Medical SE & Co. KGaA / Schlagwort(e): Sonstiges CompuGroup Medical schließt Investitionsvereinbarung mit CVC Capital Partners 09.12.2024 / 09:19 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CompuGroup Medical schließt Investitionsvereinbarung mit CVC Capital PartnersCVC kündigt freiwilliges öffentliches Übernahmeangebot an alle Aktionäre im Streubesitz an CVC plant freiwilliges öffentliches Übernahmeangebot über 22,00 Euro pro Aktie sowie anschließendes Delisting Deutlicher Aufschlag von 51,1 % auf den vo...
>Feedback from conference call: 2024 guidance maintained at lower end of range Visibility still poor on timing of government programmes (Ségur, HFA) - CompuGroup published yesterday morning Q3 2024 results reflecting a steep decline in profitability, but in line with consensus expectations. (link first take ici). However, the share price ended the session with up 7% gain. This publication was probably reassuring, given that the latest reports was full of bad news, al...
>Feedback conf. call : guidance 2024 confirmée sur le bas de fourchette. Toujours une faible visibilité sur le timing des programmes gouvernementaux (Ségur, HFA) - CompuGroup a publié hier matin des résultats T3 2024 reflétant une baisse marquée de la rentabilité, mais en ligne avec les attentes du consensus (lien first take ici). Le cours a pourtant clôturé la séance en hausse de 7%. Cette publication a probablement rassuré alors que les dernières apportaient leur d...
>Weak profitability in Q3 2024 (in line) - CompuGroup published this morning its Q3 results, which were close to expectations. Q3 revenues were down 1% y-o-y to € 283m (in line with css). In detail, AIS segment shows timid growth of 1% to € 173m (+1% vs css), still impacted by the slowdown of the non-recurring mix (additional modules, professional services, etc.). HIS’s revenues came out down at € 77m (-2% vs css) reflecting a decrease of 4% y-o-y, still disappointed ...
>Weak profitability in Q3 2024 (in line) - CompuGroup published this morning its Q3 results, which were close to expectations. Q3 revenues were down 1% y-o-y to € 283m (in line with css). In detail, AIS segment shows timid growth of 1% to € 173m (+1% vs css), still impacted by the slowdown of the non-recurring mix (additional modules, professional services, etc.). HIS’s revenues came out down at € 77m (-2% vs css) reflecting a decrease of 4% y-o-y, still disappointed ...
EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Quarter Results/Quarterly / Interim Statement CGM drives innovation in the third quarter while recording earnings decline with almost stable revenues 07.11.2024 / 07:35 CET/CEST The issuer is solely responsible for the content of this announcement. CGM drives innovation in the third quarter while recording earnings decline with almost stable revenues Koblenz - CompuGroup Medical, one of the world's leading e-health providers, recorded revenues of EUR 283.4 million in the third quarter of the 2024 financial year, s...
EQS-News: CompuGroup Medical SE & Co. KGaA / Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung CGM treibt Innovation voran, während im dritten Quartal ein Ergebnisrückgang bei nahezu stabilen Umsätzen verzeichnet wurde 07.11.2024 / 07:35 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CGM treibt Innovation voran, während im dritten Quartal ein Ergebnisrückgang bei nahezu stabilen Umsätzen verzeichnet wurde Koblenz – CompuGroup Medical, einer der weltweit führenden E-Health-Anbieter, verzeichnete im dritten Quartal des Gesc...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Personnel CompuGroup Medical appoints Prof. Dr. Daniel Gotthardt as new CEO 31.07.2024 / 18:40 CET/CEST The issuer is solely responsible for the content of this announcement. CompuGroup Medical appoints Prof. Dr. Daniel Gotthardt as new CEO Koblenz. CompuGroup Medical announced today that the Administrative Board appoints the company founder’s son, Prof. (apl.) Dr. med. Daniel Gotthardt, as CEO of CGM effective as of September 1, 2024. The current CEO Michael Rauch will leave the company in the best mutual agreeme...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.